Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia

Steven P. Treon, Joshua Gustine, Kirsten Meid, +15

Journal of Clinical Oncology

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia

Steven P. Treon, Kirsten Meid, Joshua Gustine, +11

Journal of Clinical Oncology

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia

Lian Xu, Nicholas Tsakmaklis, Guang Yang, +14

Blood

<i><scp>MYD</scp>88</i> wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival

Steven P. Treon, Joshua Gustine, Lian Xu, +16

British Journal of Haematology

<i>CXCR4</i> mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

Jorge J. Castillo, Lian Xu, Joshua Gustine, +15

British Journal of Haematology

Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes

Josephine M. I. Vos, Joshua Gustine, Helmut G. Rennke, +8

British Journal of Haematology

Glomerular DiseaseRenal PathologyImmunologyPathologyGlomerulonephritis +21

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia

Zachary R. Hunter, Lian Xu, Guang Yang, +14

Blood

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia

Zachary R. Hunter, Lian Xu, Nickolas Tsakmaklis, +17

Blood Advances

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism

Jiaji G. Chen, Xia Liu, Manit Munshi, +18

Blood

Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia

Jorge J. Castillo, Kirsten Meid, Joshua Gustine, +19

Leukemia